CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
7.52
+0.79 (11.74%)
At close: Apr 28, 2025, 4:00 PM
7.55
+0.03 (0.40%)
After-hours: Apr 28, 2025, 5:10 PM EDT
Company Description
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors.
It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Jun 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 206 |
| CEO | Kevin Hykes |
Contact Details
Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States | |
| Phone | 763 416 2840 |
| Website | cvrx.com |
Stock Details
| Ticker Symbol | CVRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001235912 |
| CUSIP Number | 126638105 |
| ISIN Number | US1266381052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kevin Hykes | President, Chief Executive Officer and Director |
| Jared Oasheim | Chief Financial Officer |
| Paul Verrastro | Chief Marketing and Strategy Officer |
| Paul Pignato | Vice President of Research, Development and Operations |
| Jonelle R. Burnham | Vice President and General Counsel |
| Tonya A. Austin SPHR | Chief Human Resources Officer |
| Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer |
| Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics |
| Robert Allen John | Chief Revenue Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | 8-K | Current Report |
| Feb 20, 2025 | SCHEDULE 13D/A | Filing |
| Feb 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 18, 2025 | 10-K | Annual Report |
| Feb 6, 2025 | SCHEDULE 13D/A | Filing |
| Feb 6, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |